Search results for "HORMONE REPLACEMENT THERAPY"

showing 10 items of 72 documents

Terminal or truncal ligation of the inferior thyroid artery during thyroidectomy? A prospective randomized trial.

2016

Abstract Introduction Thyroidectomy is a common procedure in general and endocrine surgery. The technique of ligation of inferior thyroid artery (ITA) has been invoked as a possible cause of appearance of postoperative hypocalcemia. Methods We performed a prospective randomized study involving 184 patients undergoing total thyroidectomy to evaluate the differences of truncal ligation versus distal ligation of ITA in terms of postoperative hypocalcemia, vocal fold palsy, voice and swallowing impairment. The patients were divided into group A (trunk ligation of ITA) and group B (terminal branches ligation of ITA). Results We evaluated postoperative PTH and calcemia (immediate, 6 and 12 months…

Malemedicine.medical_specialtyThyroid HormonesHormone Replacement Therapymedicine.medical_treatmentThyroid Gland030230 surgery03 medical and health sciences0302 clinical medicineSwallowingHypothyroidismmedicine.arterymedicineHumansVocal cord paralysisProspective StudiesThyroid NoduleVitamin DProspective cohort studyInferior thyroid arteryLigationAgedmultinodular goiterHypocalcemiabusiness.industryThyroidThyroidectomyinferior thyroid artery; multinodular goiter; thyroidectomyGeneral Medicineinferior thyroid arteryMiddle Agedmedicine.diseaseThyroid DiseasesSurgeryEndocrine surgerymedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisAnesthesiaThyroidectomySurgeryCalciumFemalebusinessLigationDeglutition DisordersVocal Cord ParalysisInternational journal of surgery (London, England)
researchProduct

Effects of transdermal hormone replacement therapy on levels of soluble P- and E-selectin in postmenopausal healthy women

2002

Abstract Objective: To study the adhesion molecule pattern in postmenopausal women who were not receiving hormone replacement therapy (HRT), HRT users, and fertile women. Design: Case-control study. Setting: Second University of Naples, Naples, Italy. Patient(s): Fifty healthy naturally postmenopausal women and 20 fertile women. Intervention(s): Twenty-six women received no HRT and 24 received continuous transdermal 17β−estradiol, 0.05 mg/d, plus oral acetate nomegestrol, 5 mg/d. Main Outcome Measure(s): Levels of the soluble forms of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, and P-selectin. Result(s): Women who did not received HRT …

Nomegestrolmedicine.medical_specialtyAdministration Cutaneougenetic structuresP-selectinmedicine.drug_classHormone Replacement Therapymedicine.medical_treatmentHRTVascular Cell Adhesion Molecule-1Administration Cutaneouschemistry.chemical_compoundInternal medicineE-selectinmedicineHumansICAM-1biologyEstradiolbusiness.industryCase-control studyObstetrics and GynecologyHormone replacement therapy (menopause)Megestrolmedicine.diseaseIntercellular Adhesion Molecule-1AtherosclerosisMenopausePostmenopauseP-SelectinEndocrinologyReproductive MedicinechemistryEstrogenCase-Control Studiesbiology.proteinAdhesion molecules; Atherosclerosis; HRTFemalebusinessCase-Control StudieE-SelectinAdhesion moleculesHuman
researchProduct

Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts

2018

Source at https://doi.org/10.1186/s13058-018-1073-0. Licensed CC BY-NC-ND 4.0. Background: Few published breast cancer (BC) risk prediction models consider the heterogeneity of predictor variables between estrogen-receptor positive (ER+) and negative (ER-) tumors. Using data from two large cohorts, we examined whether modeling this heterogeneity could improve prediction. Methods: We built two models, for ER+ (ModelER+) and ER- tumors (ModelER-) , respectively, in 281,330 women (51% postmenopausal at recruitment) from the European Prospective Investigation into Cancer and Nutrition cohort. Discrimination (C-statistic) and calibration (the agreement between predicted and observed tumor risks)…

OncologyHORMONE-REPLACEMENT THERAPYmedicine.medical_treatmentWHI0302 clinical medicineBreast cancerRisk FactorsEstrogen receptor030212 general & internal medicineProspective StudiesProspective cohort study2. Zero hungerIncidenceHormone replacement therapy (menopause)Middle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisRisk prediction3. Good healthEuropean Prospective Investigation into Cancer and NutritionMenopausePOSTMENOPAUSAL WOMENReceptors EstrogenPLUS PROGESTIN030220 oncology & carcinogenesisCohortFemaleRisk assessmentResearch Articlemedicine.medical_specialtyMODELSAntineoplastic AgentsBreast NeoplasmsEstrògenslcsh:RC254-282Models BiologicalRisk AssessmentVALIDATIONCàncer de mamaMAMMOGRAPHY03 medical and health sciencesBreast cancerInternal medicinemedicineHumansOncology & CarcinogenesisCancer och onkologiVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762business.industryMORTALITYKirurgiProspective cohortmedicine.diseaseEstrogenVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762Cancer and OncologySurgerybusinessEPIC1112 Oncology And CarcinogenesisBody mass indexFollow-Up StudiesBreast Cancer Research : BCR
researchProduct

Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.

2003

Objective To compare the long-term effects of oral and transdermal hormone replacement therapy (HRT) on serum homocysteine levels in postmenopausal women. Design An open, prospective, controlled study. Seventy-five healthy postmenopausal women were recruited as eligible for the study. Fifty women seeking HRT were randomized to receive continuous 17beta-estradiol, either by oral (2 mg daily; n = 25) or transdermal (50 microg daily; n = 25) administration, plus 10 mg dydrogesterone daily for 14 days of each 28-day cycle. Twenty-five women unwilling to receive hormone treatment received only calcium supplementation, representing the control group. Fasting blood samples were analyzed at baselin…

Oralmedicine.medical_specialtyAdministration CutaneouHomocysteineEstronemedicine.medical_treatmentHRTAdministration OralEstroneDydrogesteroneAdministration CutaneousGastroenterologylaw.inventionchemistry.chemical_compoundFollicle-stimulating hormoneRandomized controlled triallawReference ValuesInternal medicineMedicineHumansReference ValueProspective StudiesProspective cohort studyHomocysteineTransdermalEstradiolProgesterone Congenersbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyHormone replacement therapy (menopause)Progesterone CongenerMiddle AgedHomocysteine; HRT; TransdermalPostmenopauseProspective StudieEndocrinologychemistryDydrogesteroneDrug Therapy CombinationFemaleFollicle Stimulating HormonebusinessTransdermalmedicine.drugHumanMenopause (New York, N.Y.)
researchProduct

Effect of hormone replacement therapy (HRT) on periodontal status of postmenopausal women.

2011

Summary Background The risks/benefits balance of hormone replacement therapy (HRT) is controversial. The aim of this study was to assess the periodontal status of a postmenopausal women group receiving HRT and to determine the effects of HRT on clinical measures of periodontal disease. Material/Methods Ninety-one postmenopausal women, 52 taking HRT (HRT+) and 39 not taking HRT (HRT−), completed the study. Clinical parameters measured included visible supragingival plaque, probing pocket depth (PD) and clinical attachment level (CAL). Gingival status was recorded as gingival bleeding on probing (BOP). Previous oral contraceptive use and current and past smoking status were also assessed. Res…

Periodontiummedicine.medical_specialtygenetic structuresPeriodontal diseaseSettore MED/28 - Malattie OdontostomatologicheInternal medicineMedicineHumansEstrogen replacement therapyperiodontitisGynecologyPostmenopausal womenbusiness.industryEstrogen Replacement TherapyGeneral MedicineMiddle Agedeye diseaseshormone replacement therapypostmenopausefemaleTransgender hormone therapyhormone replacement therapy (HRT) postmenopause chronic periodontitis gingivitis femalesense organsPublic HealthbusinessgingivitisMedical science monitor : international medical journal of experimental and clinical research
researchProduct

Role of menopause and hormone replacement therapy in sleep-disordered breathing

2020

There are suggestions that the loss of female sex hormones following menopause is critical for the development or progression of sleep-disordered breathing (SDB). We conducted a review of the literature on the role of menopause and hormone replacement therapy (HRT) in SDB risk. There is an increase in SDB during the menopausal transition period, but data on an effect beyond that of increasing age and changes in body habitus are weak or absent. Early community-based, observational studies reported a protective effect by HRT on SDB prevalence, but this could possibly be explained as a healthy user effect. Interventional studies of the effect of HRT on SDB are sparse, with only a few randomize…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtymedicine.drug_classSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesSleep Apnea Syndromes0302 clinical medicineWomanPhysiology (medical)mental disordersPrevalenceHumansMedicineObesitycardiovascular diseasesSleep-disordered breathingbusiness.industrymedicine.diseaseEstrogenObstructive sleep apneaObesitynervous system diseasesrespiratory tract diseasesObstructive sleep apneaMenopauseMetabolismHormone replacement therapy030228 respiratory systemNeurologyEstrogenTransgender hormone therapySleep disordered breathingFemaleObservational studysense organsNeurology (clinical)Menopausebusiness030217 neurology & neurosurgeryHormoneSleep Medicine Reviews
researchProduct

Comparison of soft tissue body composition in postmenopausal women with or without hormone replacement therapy considering the influence of reproduct…

2001

To examine long-term effects of at least 5 years' conventional hormone replacement therapy (HRT), reproductive history and lifestyle on fat mass and muscle mass in postmenopausal women.A cross-sectional retrospective approach was used, including 64 healthy women (56-69 years, mean age 63.4 years). Hormone users were compared with age-matched non-users with respect to (a) type of HRT used (oestrogen vs oestrogen plus gestagen vs no hormones), (b) categories of oestrogens used (oestradiol-based oestrogens vs conjugated equine oestrogens vs no oestrogens) and (c) categories of gestagens used (testosterone derivatives vs progesterone derivatives vs no gestagens). Data on hormone use, reproducti…

Research designAgingmedicine.medical_specialtyPhysiologyEpidemiologyHormone Replacement TherapyPhysiologySurveys and QuestionnairesGeneticsElectric ImpedanceMedicineHumansLife StyleTestosteroneAgedRetrospective StudiesGynecologyAnalysis of VariancePostmenopausal womenAnthropometrybusiness.industryPublic Health Environmental and Occupational HealthSoft tissueMiddle AgedPhysical activity levelPostmenopauseCross-Sectional StudiesTransgender hormone therapyCase-Control StudiesMenarcheBody CompositionFemalebusinessHormoneAnnals of human biology
researchProduct

Circulating miR-21, miR-146a and Fas ligand respond to postmenopausal estrogen-based hormone replacement therapy--a study with monozygotic twin pairs.

2014

Biological aging is associated with physiological deteriorations and its’ remodeling, which are partly due to changes in the hormonal profile. MicroRNAs are known to post-transcriptionally regulate various cellular processes associated with cell senescence; differentiation, replication and apoptosis. Measured from the serum, microRNAs have the potential to serve as noninvasive markers for diagnostics/prognostics and therapeutic targets. We analysed the association of estrogen-based hormone replacement therapy (HRT) with selected microRNAs and inflammation markers from the serum, leukocytes and muscle tissue biopsy samples obtained from 54-62 year-old postmenopausal monozygotic twins (n=11 p…

SenescenceAdultmedicine.medical_specialtyAgingFas Ligand Proteinmedicine.drug_classmedicine.medical_treatmentMonozygotic twinInflammationApoptosisBiologyta3111Fas ligand“Inflamm-aging”Internal medicinemicroRNAmedicineestrogenHumansmicrornasMuscle SkeletalHormone therapyCellular SenescenceInflammationmicroRNAEstrogen Replacement TherapyapoptosisHormone replacement therapy (menopause)ta3141Cell DifferentiationEstrogenstwinsTwins MonozygoticMiddle AgedPostmenopauseAgeinghormone replacement therapyMicroRNAsEndocrinologyEstrogenFemalemedicine.symptomBiomarkersDevelopmental BiologyHormoneMechanisms of ageing and development
researchProduct

Italian Association of Sleep Medicine (AIMS) position statement and guideline on the treatment of menopausal sleep disorders

2019

Insomnia, vasomotor symptoms (VMS) and depression often co-occur after the menopause, with consequent health problems and reductions in quality of life. The aim of this position statement is to provide evidence-based advice on the management of postmenopausal sleep disorders derived from a systematic review of the literature. The latter yielded results on VMS, insomnia, circadian rhythm disorders, obstructive sleep apnea (OSA) and restless leg syndrome (RLS). Overall, the studies show that menopausal hormone therapy (MHT) improves VMS, insomnia, and mood. Several antidepressants can improve insomnia, either on their own or in association with MHT; these include selective serotonin reuptake …

Sleep Initiation and Maintenance Disordermedicine.medical_treatmentSerotonin and Noradrenaline Reuptake InhibitorPosition statementSleep medicine0302 clinical medicineSleep Initiation and Maintenance DisordersCognitive behavioraltherapy for insomnia (CBT-I)InsomniaSleep Wake Disorder030212 general & internal medicineContinuous positive airway pressureRestless legs syndromeSerotonin and Noradrenaline Reuptake InhibitorsCognitive behavioraltherapy for insomnia (CBT-I); Hormonereplacementtherapy (HRT); Menopause; Position statement; Sleepdisorders; Vasomotorsymptoms (VMS)Sleep Apnea Obstructive030219 obstetrics & reproductive medicineContinuous Positive Airway PressureDepressionObstetrics and GynecologySerotonin Uptake InhibitorAntidepressive AgentsMenopauseCognitive behavioral therapyCognitive behavioral therapy for insomnia (CBT-I)SleepdisordersAntidepressive AgentFemalemedicine.symptomMenopauseSelective Serotonin Reuptake Inhibitorsmedicine.drugHumanSleep Wake Disordersmedicine.medical_specialtyHormone Replacement TherapyVasomotor symptoms (VMS)MirtazapineCognitive behavioral therapy for insomnia (CBT-I); Hormone replacement therapy (HRT); Menopause; Position statement; Sleep disorders; Vasomotor symptoms (VMS); Antidepressive Agents; Cognitive Behavioral Therapy; Continuous Positive Airway Pressure; Depression; Exercise; Female; Humans; Mirtazapine; Quality of Life; Restless Legs Syndrome; Serotonin Uptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sleep; Sleep Apnea Obstructive; Sleep Initiation and Maintenance Disorders; Sleep Wake Disorders; Hormone Replacement Therapy; MenopauseMirtazapineSettore MED/10 - Malattie Dell'Apparato RespiratorioHormone replacement therapy (HRT)Hormonereplacementtherapy (HRT)General Biochemistry Genetics and Molecular Biology03 medical and health sciencesRestless Legs Syndromemental disordersmedicineHumansExerciseSleep disorderCognitive Behavioral Therapybusiness.industryVasomotorsymptoms (VMS)medicine.diseasenervous system diseasesObstructive sleep apneaMenopause sleep disorders vasomotor symptoms (VMS) hormone replacement therapy (HRT) Cognitive Behavioral Therapy for Insomnia (CBT-I) Position StatementPhysical therapyQuality of LifebusinessSleep
researchProduct

The Challenges in Moving from Ageing to Successful Longevity

2014

During the last decades survival has significantly improved and centenarians are becoming a fast-growing group of the population. Human life span is mainly dependent on environmental and genetic factors. Favourable modifications of lifestyle factors (e.g. physical activity, diet and not smoking) and healthcare (e.g. effective vascular disease prevention) have also increased human life span. Genetic factors contribute to the variation of human life span by around 25%, which is believed to be more profound after 85 years of age. It is likely that multiple factors influence life span and we need answers to questions such as: 1) What does it take to reach 100?, 2) Do centenarians have better he…

ageing longevity age-related diseasesGerontologyAgingYounger ageHormone Replacement Therapymedia_common.quotation_subjectLongevityPopulationHealth careAnimalsHumansMedicineeducationLife Stylemedia_commonSettore MED/04 - Patologia GeneraleAged 80 and overPharmacologyeducation.field_of_studyAnimalbusiness.industryLongevityCognitionDietNutrigenomicsAgeingLife expectancyCardiology and Cardiovascular MedicinebusinessHumanCurrent Vascular Pharmacology
researchProduct